A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
Clinical trial NCT07000617 · RECRUITING
Trial details
- NCT number
- NCT07000617
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-21
- Primary completion
- 2026-12-01
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.